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From the 
President 
As we all know, the current climate of 
medicine seems to be as fickle as the 
weather in New England. No matter how 
well we think we are prepared, change often 
seems just one step ahead of us. 
Still, there are occasionally changes which 
occur for which members of our staff are 
responsible and which keep pace with 
changes in our environment. Our medical 
environment demands initiatives in 
Operations Improvement (01) for it is only by 
providing the highest quality care in an 
efficient fashion that funds will be available 
for program development and technology. 
The development of Care Management 
Pathways championed by our own David 
Caccese, and their implementation by 
members of our staff is one example of how 
we physicians can help to control our 
medical economic environment. The 
selection of major joint preferred vendors 
and establishment of a total joint clinical 
pathway by the Division of Orthopedics two 
years ago is another example. 
Recently, members of our staff were 
involved in another initiative which should 
have a significant impact on 01 and, I feel, 
their achievement deserves public 
recognition. In fiscal year 1997, 
approximately 265 pacemakers and 100 
implantable defibrillators (ICDs) were placed 
in patients at Lehigh Valley Hospital at a 
(Continued on Page 2) 
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cost of about $4.5 million. Luis Constantin, Jack Fitzgibbons, 
Chuck Hoover, Lynn Morris, Tony Panebianco and Steve 
Zelenkofske represented our staff on an 11 member committee. 
It was the charge of this committee to examine the purchasing 
practice of pacemakers and ICDs. As a result of the superb work 
of these 11 individuals, three preferred vendors were identified - · 
who could meet our expectations of the highest quality medical 
technology at a cost savings projected to be $1.2 million during 
the first year alone. That's a considerable financial resource 
which should now be available for use in other patient care 
initiatives in the future. It is this type of dedication to patient care 
and foresight into the financial future which represents some of 
the best characteristics of an exceptional medical staff; If we are 
to prosper as a staff at this institution, more of this will be 
necessary. For now, though, congratulations Luis, Jack, Chuck, 
Lynn, Tony and Steve for a job exceedingly well done! 
I do have additional follow-up on efforts by the 
Telecommunications Department to meet the concerns we, as a 
staff, have expressed about our paging system. You should have 
recently received a 96-page, physician-only, confidential booklet 
listing each member of our staff, office phone number and pager 
number. Also, inservices have been held with hospital employees 
to encourage their use of the direct page system. Hopefully, 
these two initiatives will increase the number of direct pages we 
can place and decrease the overload of the paging system. If you 
have not received this booklet, additional copies are available in 
the Medical Staff Services Office. 
This month, the Lehigh Valley Hospital/Muhlenberg Hospital 
Center physician transition team will begin their discussions about 
one of the most controversial issues with which we at Lehigh 
Valley Hospital deal, i.e. the Staff Development Plan. I am sure 
this will prove to be a very interesting series of discussions as the 
"open" staff model at Muhlenberg Hospital Center and the 
"closed" staff model at Lehigh Valley Hospital are examined as we 
attempt to merge these very different medical staffs. I will report 
back to you as these talks become more substantive. 
Finally, we all need something to look forward to during the cold, 
dark, depressing days of Winter. The third triennial Physician 
Recognition Dinner will be held Saturday, March 28, 1998 at the 
Holiday Inn in Fogelsville. I look forward to sharing an evening of 
fun, camaraderie, and celebration with you all. 
Keep up the superb work! 
~ 
Robert X. Murphy, Jr., MD 
President, Medical Staff 
L VH Offering the Latest Treatment < 
for Prostate Cancer 
When Frederick Fried of East Greenville learned he had 
prostate cancer, he had some serious decisions to make 
about treatment. 
But at 77, Mr. Fried didn't want to risk complications in surgery 
or spend six weeks recovering from surgery. He didn~ want to 
undergo the eight weeks of external beam.radiation therapy 
either or chance its side affects. 
Luckily, Lehigh Valley Hospital and Health Network's John and 
Dorothy Morgan Cancer Center was able to offer him the latest 
treatment for prostate cancer, a non-incision outpatient 
procedure that involves implanting radioactive seeds into the 
prostate. The Morgan Cancer Center is the only facility in the 
Lehigh Valley performing the procedure, and on December 11, 
Mr. Fried was the first patient to undergo the treatment here. 
"Only on the first day after the procedure, I experienced a bit 
of burning during urination, and it was a little hard to sit, • Mr. 
Fried said. "But right away, I was back to normal day 
activities, and I feel great. I'm very happy with everything." ( 
Through the treatment, a urologist and a radiation oncologist 
implant about 60 to 100 radioactive seeds, no larger than 
grains of rice, into the prostate with a needle. The procedure, 
called brachytherapy, is an alternative to surgery or external 
beam radiation therapy for people who have early cases of 
prostate cancer. 
"We give the patient an ultrasound so we know exactly where 
to place the seeds," said David L. Clair, MD, urologist, who 
performed the first procedure with Charles F. Andrews, MD, 
radiation oncologist. "This allows us to give a higher dose of 
radiation without delivering it to other organs in the area." 
Other than mild discomfort a day or two after the implantation, 
there are few side effects compared to radiation and surgery. 
"The patient won't get as much rectal irritation, not as many 
urinary problems and potency rates are better," Dr. Andrews 
said. 
The seed implant procedure is more than 20 years old; 
however, it has been improved during the last 10 years in 
Seattle, Wash. 
(Continued on Page 3) 
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'The old way, a surgeon would actually open the abdomen, 
localize the prostate and put the seeds directly into the gland," 
Dr. Andrews said. "You couldn't get the seeds equally spaced 
that way. With an ultrasound and a needle, you get a nice 
even distribution." 
The Morgan Cancer Center did not adopt the procedure 
sooner because doctors were waiting for the long term results 
from Seattle. "For patients selected to undergo the procedure, 
brachytherapy1s an effective alternative to surgery and 
external beam radiation," Dr. Andrews said. "Now, there's a 
big demand for the procedure." 
It's so popular that the Morgan Cancer Center has patients 
scheduled up until March. The procedure has also caught on 
nationwide, causing a delay in the production of seeds. 
"At this point, it takes 12 weeks after ordering to receive the 
seeds," said Nancy Earley, director of radiation oncology. 
"The manufacturer anticipates reducing that to two weeks in 
the early spring or summer." 
Prostate Cancer is the most common cancer among men and 
the second leading cause of death of men. In 1996, about 
250,000 men were diagnosed with prostate cancer, and in 
1997, more than 300,000 were diagnosed. 
Mr. Fried, who received a free prostate screening at the 
Morgan Cancer Center a few years ago, learned there that he 
had an enlarged prostate, a common condition in men older 
than 60. Since then, he has been getting regular prostate 
screenings, which made it possible for doctors to find the 
cancer in its early stage. 
"Mr. Fried was a good candidate for the procedure, and he is 
doing great," Dr. Clair said. "But is he cured? Well, we don't 
know yet, but I expect the cancer to shrink fast. • 
Meanwhile, Mr. Fried is grateful that he was able to undergo 
the latest treatment. "I am blessed that they caught the cancer 
this early and that I have doctors with the newest ideas," he 
said. "I am really pleased with Lehigh Valley Hospital. There 
are angels everywhere." 
As of January 15, 1998, AUTOPSY 
REPORTS are now available on-line in the 
. PHAMIS LastWord system. 
New L VHN Program Finds, Treats 
Pelvic Pain 
"Take a couple of aspirins and lie down for half an hour" 
usually works for menstrual pain. But for millions of women, 
pelvic pain is not related to a gynecological problem, is difficult 
to diagnose and is not something that goes away easily. 
To address this health concern, Lehigh Valley Health Network 
(LVHN) has developed a chronic pelvic pain program, which is 
among the first in the country to apply a minimally-invasive 
procedure called "conscious pain mapping" to help with 
diagnosis. 
"Pelvic pain accounts for one in 10 visits to the gynecologist 
and over $1 billion each year in medical costs," said Craig J. 
Sobolewski, MD, LVH gynecologist and director of the 
program. "Tragically, many women never get an accurate 
diagnosis of what is wrong." 
"Only a minority of the cases are gynecologically related," he 
continued. "What makes it so tricky is that pain felt in one 
area doesn't necessarily originate there. Just as a heart attack 
can cause pains in the arm, pain in the pelvis can be 
gynecologic, gastrointestinal, urinary, muscle- or bone-related, 
or even from appendicitis." 
Moreover, the problem often is more than physical. Half of the 
women with chronic pelvic pain have a history of physical or 
sexual abuse and two-thirds have a history of major 
depression. Even without those issues, pain that goes on for 
months or years can become all-consuming, disrupting work, 
sexuality and family life. "We recognize there are two parts to 
every pain - the physical part and the 'volume knob' or the 
way you perceive the pain psychologically," Dr. Sobolewski 
said. "If you ignore the psychological factors, you are leaving 
out a whole aspect of patient care that can determine the 
treatment's success.· 
One of Sobolewski's key diagnostic tools is laparoscopy, a 
minimally invasive procedure in which long, thin instruments 
are inserted into the pelvis through tiny incisions. The 
specialist views the area on video while performing diagnosis 
and treatment. With today's fiberoptics, these instruments can 
be so narrow the patient needs only local anesthesia. 
An increased amount of traditional gynecological surgery is 
now being performed through minimally invasive surgery or 
operative endoscopic surgery. Once limited to tubal surgery 
such as that for sterilization or treatment of ectopic pregnancy, 
(Continued on Page 4) 
Medical Staff Progress Notes February, 1998 ~ Volume 10, Number 2 Page4 
(Continued from Page 3) 
this procedure has grown rapidly to encompass surgery for 
gynecological malignancy, pelvic reconstruction, correction of 
incontinence or pelvic organ prolapse, removal of ovarian or 
pelvic tumors, and complete or vaginally-assisted 
hysterectomy. 
A few centers in the country, including LVH, are now applying 
micro-laparoscopy to pelvic pain mapping under conscience 
sedation. The idea came about after a patient asked her 
surgeon what "pain" looked like, Dr. Sobolewski said. 
With conscious pain mapping, the patient is sedated, but 
remains awake to give feedback as the surgeon gently probes 
to produce the exact pain the patient has been feeling. In 15 
to 20 percent of the cases, conscious pain mapping will find a 
cause for the pain that could not be detected otherwise, said 
Dr. Sobolewski, who believes that this procedure will replace 
standard diagnostic laparoscopy in patients who need surgical 
evaluation for their pain. 
But besides the physical examination, patients in LVH's 
chronic pelvic pain program also receive a psychological 
screening. Depending on their needs, patients are treated or 
referred to other specialists. 
"One of the most important aspects of patient care is support," 
Dr. Sobolewski said. "Typically, chronic pelvic pain is a 
physical problem that has also created a psychological one. 
Given the holistic way our program works, we're able to assure 
each patient that we'll stick with her until we figure out what 
the problem is and then make her as well as we possibly can." 
Beware of the Invisible Force!! 
The inpatient entrance to Lehigh Magnetic Imaging Center is 
secured and locked for a reason ... when you pass through 
those doors, you are entering the magnetic field. It is often 
difficult to understand because you can't see or feel the 
presence of a magnetic field. Lockers are provided at LMIC's 
inpatient entrance for L VH staff to secure their 10 badges, 
wallets, cellular phones, etc. If you take these items into the 
magnetic field, their data will be erased and they will no longer 
function. Additionally, anyone with a pacemaker or aneurysm 
clips in the brain CANNOT enter into this area. The same 
conditions that prohibit a person from having an MRI study 
apply to those entering the magnetic field. Please understand 
that when an LMIC employee speaks to you on the intercom 
and asks questions, it is for your own personal safety. Feel 
free to call LM IC at 7 40-9500 if you have any questions or 
concerns. 
Medicare Covers More Preventive 
Services 
In a recent memo from the Hospital & Healthsystem 
Association of Pennsylvania, big changes in Medicare this 
year reflect a new emphasis on preventive health. As of 
January 1, 1998, the program covers screening mammograms 
(for breast cancer) every year, versus every two years, in 
women over 40. Medicare also covers pap smears and pelvic 
exams once a year for women at high risk for disease and 
every third year:for others. Colorectal cancer screenings are 
covered for the first time for Medicare beneficiaries over age 
50. 
Starting July 1, the program will cover bone-density tests for 
women at high risk of developing osteoporosis. In addition, 
prostate cancer screenings for men over 55 will be covered 
beginning January 1, 2000. 
Cardiac Rehab Relocates 
On January 19, the Cardiac Rehabilitation Department 
relocated to 1243 S. Cedar Crest Boulevard, Lower Level. 
The new telephone number is (61 0) 402-5915; the new fax 
number is (610) 402-5917. 
The new location provides larger exercise floor space, 
educational consult rooms, body composition and screening 
room, plus improved locker rooms. 
The department continues to offer Phase I inpatient cardiac 
rehab for both medical and surgical patients, Phase II 
monitored outpatient services for up to 12 weeks, and Phase 
Ill unmonitored maintenance outpatient services for up to 12 
months. 
Please feel free to visit the new facility at any time. 
Radiology Orders 
When referring a patient for radiology services, 
please remember to include a diagnosis and/or 
any pertinent information for the reason of 
examination. If you have any questions regarding 
radiology services, please contact the Department~ 
of Radiology at 402-8080. \l .. 
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Dr. Mishriki Puzzles Physicians 
with Pictures 
Yehia Y. Mishriki, MD, Chief, Division of Ambulatory 
Care, snaps a significant number of pictures when he's at 
work. Chances are you won't see his photographs 
displayed on his office walls or in any network 
publications. They're not smiling faces, beautiful sunsets, 
expansive landscapes or the like. They don't focus on 
what's beautiful, but rather on what's not. 
Dr. Mishriki has taken hundreds of slides of rashes, 
tumors, infections and other common and unusual 
medical conditions he's diagnosed and treated over the 
past seven years of his 14 years in practice. A dozen of 
them are being published under the heading "Puzzles in 
Practice" in the journal Postgraduate Medicine (PGM). 
Dr. Mishriki proposed "Puzzles in Practice" to PGM's 
editors as a regular feature for helping physicians 
diagnose uncommon medical conditions or routine ones 
that are not easily identified. One photo will appear each 
( ·month in the journal, along with text describing 
symptoms, possible and correct diagnoses, and 
treatment, all written by Dr. Mishriki. 
"I really believe that a picture is worth a thousand words," 
says Dr. Mishriki, who is also on the faculty of Penn 
State.'s College of Medicine at Hershey, and teaches both 
medical students and residents at L VH. "I often show my 
slides when I'm teaching. You can read a lot about a 
condition, but until you see it, it's not really the same." 
His first "puzzle" appeared in PGM's October issue. "The 
Case of the Second Tongue" featured a full-color photo 
of a patient's open mouth, tongue lifted and drawn 
toward the back of the pallet. The base of the mouth was 
red and swollen. Dr. Mishriki's diagnosis: acute bacterial 
sialadenitis of the submandibular glands, of course. 
Dr. Mishriki has submitted 11 other cases, eight of which 
have been accepted by the journal. Some of the 
upcoming conditions include pin worms, glomus tumors 
and angioedema, a hereditary illness caused by a 
~eficiency of a certain protein. Admittedly, most 
physicians won't treat more than two to four cases of 
angioedema in their career, says Dr. Mishriki. But the 
looking and learning process is relevant nonetheless to 
medical education. 
Where does he get the time and energy to extend his 
routine 12-hour days to include researching and writing? 
"I like to write. It's a great diversion from my clinical and 
teaching duties," Dr..Mishriki noted. "Besides, it doesn't 
really take that much more time." One case took him 
only 30 minutes to write after a quick literature search. 
Also, since starting his work on "Puzzles in Practice," two 
residents have helped with the research for next year's 
series. "This way, they'll have their work published, and I 
get the help I need," he says. 
Diagnosing uncommon ailments may not be a snap to 
young physicians, but focusing on "Puzzles in Practice" 
each month can help them learn what to look for when 
assessing patients' health. 
Support Group Now Available for 
Elderly Amputees and Their Families 
Meetings are held on the fourth Monday of the 
month in Classroom 1 in the Anderson Wing of 
Lehigh Valley Hospital (Cedar Crest & 1-78), from 7 
to 8:30p.m. 
The next meeting will be held on Monday, February 
23. The topic of discussion will be "Physical 
Therapy." 
For more information, contact Pat Matula, RN, 
Outcomes Coordinator, at 402-1733. 
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Health Page Offers Two Direct Page 
Alternatives 
Don't like to wait in line? Who does? That's what 
happens frequently when you call Ext. 8999 to have 
someone paged, rather than using direct paging. The 
paging operators are swamped with calls, 120,000 of 
them per month, mostly for pages. So callers are put on 
"hold" and answered in the order they're received. 
Sometimes this can take several minutes. 
Fortunately, now there are two different ways you can 
direct page to avoid the wait. The first alternative is the 
Direct Dial "5100" Paging System, and it's very easy to 
use. Just dial 5100, enter the four-digit pager ID, plus the 
"#" sign and your seven-digit call-back number plus the 
"#" sign, then hang up. 
Don't know the pager number of the person you want to 
contact? That's easy. Just go into e-mail, "directory of e-
mail IDs," type in the last name of your contact, then "Q" 
beside the name of the person you want to page. The 
next screen will display the directions for paging that 
person. 
The second alternative is the Direct Dial "Paging by 
Name" System. To use this system, dial5100. The 
computer will respond "Please enter Pager ID to page, 
followed by the"#" sign. If you know the four-digit pager 
ID, just enter the number. If you don't know the number 
and don't have time to check the e-mail directory, enter 
* 2 #as soon as the above computer response begins. 
The computer will respond "Press the first four digits of 
the person's last name." Enter the first four letters of the 
person's last name. For "Q" or "Z" press Zero. If an 
exact match is found, the computer will prompt the caller 
to select the correct pager. For example, "press 1 to 
page John Doe, press 2 to page Jim Drake, etc. Press* 
to repeat choices." Enter the desired selection. The 
computer will respond with the pager ID, the name of the 
person you are paging, and the status of that pager. 
"Please enter your call back number, followed by the ''#" 
sign." Enter your call back nu.mber, followed by the''#" 
sign. The computer will respond, "Paging, the name, and 
Good-bye." Then, hang up the phone. If the Paging 
System finds more than nine exact matches, it will 
transfer the call to the Paging Operator. 
According to John W. Hart, Vice President, 80 percent of 
pages throughout the hospital industry are direct, but not 
at LVHN. "Unfortunately, this is reversed here. Eighty- ( 
five percent of calls to our operators are requests to have 
someone paged," Mr. Hart said. "This creates an 
overwhelming burden on the operators and often results 
in unnecessary delays." 
''Through these direct paging alternatives, we're just 
asking staff to give the operators a break, to start paging 
people directly instead of through the operators." 
In addition to these direct dial paging systems, 
which should eliminate a significant amount of 
operator-assisted pages, updated rolodex labels 
that include physicians' pager numbers have been 
distributed to all patient care units to promote the 
use of the Direct Dial "5100" system on the units. 
The rolodex labels were accompanied by a memo 
to the Nursing Directors of each unit which instruct 
each individual to page physicians responsibly in 
accordance with the on-call guidelines established 
by their practice. In addition, before 8 a.m., after 5 
p.m., and on weekends, individuals have been 
instructed to contact physicians through their 
answering service via their office number. 
If you have any concerns regarding this issue, 
please contact Janet M. Seifert in Physician 
Relations at 402-8590. 
( 
( 
Medical Staff Progress Notes February, 1998 X Volume 10, Number 2 Page7 
Depression is More than the Blues 
Everyone gets the blues or feels sad from time to time. 
However, if a person experiences these emotions 
intensely and for long periods of time, it may signal 
clinical depression, a condition that requires treatment. 
Clinical depression affects the total person- body, 
feelings, thoughts, and behaviors - and comes in various 
forms. Some people have a single bout of depression; 
others suffer recurrent episodes. Still others experience 
the severe mood swings of bipolar disorder- sometimes 
called manic-depressive illness -- with moods alternating 
between depressive lows and manic highs. 
Symptoms of Depression Include: 
• Persistent sad or "empty" mood 
• Loss of interest or pleasure in ordinary activities, 
including sex 
• Decreased energy, fatigue, being "slowed down" 
• Sleep disturbances (insomnia, early-morning waking, 
or oversleeping) 
• Eating disturbances (loss of appetite and weight, or 
weight gain) 
• Difficulty conc~ntrating, remembering, making 
decisions 
• Feeling of hopelessness, pessimism 
• Feelings of guilt, worthlessness, helplessness 
• Thoughts of death or suicide, suicide attempts 
• Irritability 
• Excessive crying 
• Chronic aches and pains that don't respond to 
treatment 
Symptoms of Mania Include: 
• Inappropriate elation 
• Irritability 
• Decreased need for sleep 
• Increased energy and activity 
• Increased talking, moving, and sexual activity 
• Racing thoughts 
• Disturbed ability to make decisions 
• Grandiose notions 
• Being easily distracted 
In the Workplace, Symptoms of Depression Often 
May Be Recognized by: 
• Decreased productivity 
• Morale problems 
• Lack of cooperation 
• Safety risks, accidents 
• Absenteeism 
• Frequent statements about being tired all the time 
• Complaints of unexplained aches and pains 
• Alcohol and drug abuse 
Get an Accurate Diagnosis 
If four or more of the symptoms of depression or mania 
persist for more than two weeks, or are interfering with 
work or family life, a thorough diagnosis is needed. This 
should include a complete physical checkup and history 
of family health problems as well as an evaluation of 
possible symptoms of depression. 
When you need to talk ... 
... help is just a phone call away. 
PHYSICIAN ASSISTANCE 
PROGRAM 
To arrange a confidential appointment 
or for more information, 
call (610) 433-8550 or 1-800-327-8878. 
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Participants Needed for Research Study 
to Treat an Often Serious Complication 
of Type 2 Diabetes 
Researchers at Lehigh Valley Hospital (LVH) are studying 
ways to offer new hope to people with Type 2 Diabetes. About 
16 million people in the United States have diabetes with 90 to 
95 percent having Type 2, in which the body develops a 
relative resistance to insulin usually in adulthood. Scientists 
have learned that tightly controlling high blood pressure and 
blood glucose levels have a major impact on slowing the 
progression of kidney disease. This trial will study a new 
investigational use of a marketed antihypertensive drug to 
determine if it will slow the progression of kidney disease in 
people with Type 2 Diabetes with high blood pressure and 
hypertension. 
Between 10 and 40 percent of people with Type 2 Diabetes 
will develop kidney disease and African Americans, Native 
Americans and Hispanics are at even greater risk. Most 
people are unaware of the warning signs. 
"A significant amount of research has been carried out in the 
Type 1 Diabetes population, but the Type 2 is a different 
animal," said Nelson Kopyt, DO, clinical investigator for the 
study at LVH. "Because Type 2 Diabetes is a hereditary 
disease that will probably affect future generations, 
participants in this study will not only be helping the general 
community, but their own family." 
Diabetic nephropathy is a progressive disease leading to end-
stage renal disease (ESRD), a serious condition in which the 
kidneys fail to rid the body of wastes. Symptoms related to 
kidney failure usually occur only in late stages of the disease, 
when kidney function has diminished to less than 25 percent 
of normal capacity. Kidney disease of diabetes exists silently 
for many years and can lead to dialysis, a kidney transplant or 
even death. Moreover, approximately two-thirds of adults with 
diabetes have hypertension which, when not tightly controlled, 
accelerates the loss of kidney function. 
"Besides being a social and clinical problem, Type 2 Diabetes 
has major economic consequences," Dr. Kopyt said. He noted 
that there are currently 250,000 dialysis patients in the United 
States alone with a growth rate of 10 percent. The current 
cost of the care of this population is in excess of $11 billion per 
year and increasing exponentially. 
According to Dr. Kopyt, this trial focuses on trying to prevent 
the progression of diabetic kidney disease above and beyond 
the benefits received simply by controlling blood pressure. 
Participants will receive one of two study drugs, both are FDA 
approved. Their blood pressure and blood glucose levels will 
be closely monitored and the levels of protein in their urine w~ 
be checked to measure the activity of the diabetic kidney 
disease. 
People with Type 2 Diabetes who have signs of diabetic 
kidney disease may qualify for this study if they have any of 
the following symptoms: protein in urine, diagnosed kidney 
problems, eyesight problems related specifically to diabetes, 
weight gain, ankle and leg swelling, leg cramps and frequent 
trips to the bathroom at night. Anyone who participates in the 
study will still be under the direct care and supervision of their 
primary doctor, who will receive regular reports on all 
medications, lab tests and blood pressure readings. 
People between the ages of 30 and 70 with type 2 Diabetes, 
hypertension and kidney disease who are interested in being 
screened to determine their eligibility for the clinical trial at 
LVH should call (610) 402-0544. 
MS Attack Antegren ® Study 
Neurosciences Research is currently seeking participants for t~ 
research study of a possible treatment for acute attacks in ( 
people with relapsing-remitting or secondary progressive 
Multiple Sclerosis (MS). 
To be eligible for the Antegren (natalizumab) research study, a 
participant must: 
• Be between the ages of 18 and 65 
• Have a diagnosis of MS 
• Be in generally good health 
• Not be using immunomodulatory drugs like a-interferon or 
copolymer-1 
• Be experiencing an acute attack or exacerbation of MS 
Attacks can be variable in severity but study treatment must 
be started early. If you wish to participate in the study, you 
must contact the investigator within no more than 72 
hours of the onset of the attack. 
For more information regarding the Antegren study, including 
more detailed eligibility criteria and side effect profile, please 
contact Nancy Eckert, RN, Clinical Research Specialist, 
Neurosciences Research, at 402-9332, or Alexander D. 
Rae-Grant, MD, Division of Neurology and Principal 
Investigator of the study, at 402-8420. 
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Flu Season Arrives 
( rhe flu season has definHely arrived as indicated by a 
significant number of inpatients with cultures positive for 
Influenza A. Infection Control, in their quest to reduce 
nosocomial infections, is aggressively following suspicious and 
confirmed cases of influenza and would like to offer a few 
notes for managing these patients in the hospital environment. 
( 
• Cases admitted to the hospital with influenza high on the 
differential list of diagnoses should be placed on Droplet 






Cases can be confirmed by viral culture or made 
clinically (high fever, severe myalgia, multiple cases, short 
(three day) incubation). Viral culture kits are available 
through the Outpatient Department, Emergency 
Departments, or by calling 402-8170. 
Rimantadine (Fiumadine) at 100 mg twice a day is helpful 
for prevention or therapy for Influenza Type A. Modify 
dosage to once a day for renal insufficiency and/or >65 
years. LVH costis $1.34/100mg tablet (AWP 
$1.62/100mg tablet). The side effects are less than with 
Amantadine (Symmetrel). 
Infection Control will notify the physicians of roommates of 
patients identified with influenza to alert them to the 
potential exposure. In these instances, it is 
recommended the physician inquire about vaccination 
history and watch for flu-like symptoms in unvaccinated 
patients. 
Patients vaccinated for influenza post exposure should be 
continued on Rimantadine for 14 days allowing for the 
vaccine to take effect. 
• Although the optimal time for influenza vaccination is 
October through mid-November, healthcare providers 
should continue to offer influenza vaccine up to and even 
after influenza activity has been detected in the 
community, particularly to those persons at high risk for 
influenza-related complications. 
Witnessing the admissions related to complications from 
influenza serves as a constant reminder of the need for high 
risk individuals to be placed on a yearly vaccination schedule , 
for influenza by their healthcare provider. It also reminds us 
( .. dl of our responsibility as healthcare providers to be 
vaccinated as well to reduce the risk of transmission to our 
patients. 
Breast Cancer Study Results 
Announced 
Researchers from the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) announced the results of a large-scale 
trial designed to determine a more effective treatment for 
women with breast cancer. Results from this study, published 
in the Journal of the National Cancer Institute, indicate that 
women whose breast cancer is estrogen-receptor-positive, 
and has not spread to their lymph nodes, were less likely to 
have a recurrence of cancer when treated with both 
chemotherapy and tamoxifen. This type of breast cancer is 
diagnosed in 15-30 percent of women with this disease. 
"In less than a decade, we have now shown the benefit of a 
unified approach to the management of women with breast 
cancer. All women with breast cancer benefit from 
chemotherapy regardless of their menopausal, nodal, and/or 
receptor status," said Bernard Fisher, MD, Scientific Director of 
the NSABP and Distinguished Service Professor in the 
Department of Surgery at the University of Pittsburgh . 
"This shows that trials like these are of value in determining 
effective new treatments for disease," said David Prager, MD, 
the clinical investigator for this NSABP trial held at Lehigh 
Valley Hospital. "These services are available through Lehigh 
Valley Hospital." 
The study involved 2,363 patients who were randomly 
assigned to one of three treatment groups; 788 women 
received tamoxifen alone, 786 women received tamoxifen and 
methotrexate and fluorouracil followed by leucovorin, and 789 
women received tamoxifen combined with cyclophosphamide, 
methotrexate, and fluorouracil. After five years of follow-up, 
patients who received any combination of chemotherapy plus 
tamoxifen were significantly more likely to be disease-free --
90 percent compared to 85 percent for those who received 
only tamoxifen. 
The NSABP is a cooperative group under the aegis of the 
NSABP Foundation, Inc. that conducts clinical trials in breast 
and colorectal cancer. Based in Pittsburgh, Pa., the group is 
funded primarily by the National Cancer Institute. To date, 
more than 40,000 women and men have entered NSABP 
clinical trials. Results from these trials have enhanced 
management of breast and colorectal cancer, and improves 
the standard of care. 
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Smoking and Your Patients ... 
... Did You Know? 
Studies indicate that patients have a greater rate of success in 
quitting smoking and remaining abstinent after one year when 
their physician takes a role in advising and assisting them to 
quit. 
Training is available for you and your staff to help you in 
assisting your patients to stop smoking. "How to Help Your 
Patients Stop Smoking" is a step-by-step guide developed by 
the National Cancer Institute. The guide employs a team 
approach to make maximum use of your time, and includes 
training your office staff for additional support and follow-up. 
The training can be done in one hour and is available at no 
charge. 
For more information, contact the Coalition For a Smoke-Free 
Valley at 402-7460. 
Library News 
Ovid Training 
To schedule a one-on-one OVID (MEDLINE) training session, 
please call Barbara lobst, Director of Library Services, at 
402-8408. 
New Additions at Cedar Crest & I· 78 
"Manual of Emergency Medicine," 6th ed. 
Author: M.J. Bresler, et al. 
Call No. WB 39 8842 1998 
"Surgical Problems Affecting the Patient with Cancer: 
Interdisciplinary Management" 
Author: A. Lefor 
Call No. QZ 200 S9615 
"Campbell's Operative Orthopaedics," 9th ed. 
Author: S.T. Canale, et al. 
Call No. WE 168 C1921 (Reference Section) 
"Dictionary of Medical Syndromes," 4th ed. 
Author: S. Magalini, et al. 
Call No. WB 15 D554 (Reference Section) 
(Also available in the 17th & Chew Library) 
"Cancer: Principles and Practice of Oncology," 5th ed. 
Author: V. Devita, et al. 
Call No. QZ 200 C21537 (Reference Section) ( 
New Additions at 17th & Chew 
"Infections in Pregnancy," 2nd ed. 
Author: L. Gilstrap, et al. 
Call No. WQ 256 G489i 
"Primary Care of the Newborn," 2nd eel. 
Author: H. Seidel, et al. 
Call No. WS 18.2 P952 
"Textbook of Child and Adolescent Psychiatry," 2nd ed. 
Author: J. Wiener 
Call No. WS 350 T355 
Congratulations! 
Sam Bub, MD, Department of Family Practice, was recently 
notified by the American Medical Directors Certification 
Program, Inc., that he has been recertified as a Certified 
Medical Director of a Long Term Care Facility. Dr. Bub was (. 
one of 95 Certified Medical Directors who completed the 
requirements for recertification. 
Jane Dorval, MD, Chief, Division of Physical Medicine and 
Rehabilitation, has been appointed as a board member of 
CARF (the Rehabilitation Accreditation Commission). CARF is 
a national advisory committee to revise standards for 
outpatient rehabilitation medicine. 
Gene H. Ginsberg, MD, Division of General Internal 
Medicine/Geriatrics, was recently notified by the American 
Medical Directors Certification Program, Inc., that he has been 
granted the title of Certified Medical Director of a Long Term 
Care Facility (CMD). Dr. Ginsberg was one of 100physicians 
who completed the CMD requirements. 
Debra L Kruse, MD, Division of General Pediatrics, was 
informed that she passed the General Pediatrics Certifying 
Examination given in October and has become a diplomate of 
the American Board of Pediatrics. 
( 
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Papers, Publications and 
( Presentations 
Two articles, authored by several members of the 
Medical Staff, were published in Volume 6, Number 6, 
November/December 1997, of The Journal of Maternal-
Fetal Medicine. 
The first article - "Does Centralized Monitoring Affect 
Perinatal Outcome?" - was authored by Patrice M. 
Weiss, MD, Division of Primary Obstetrics and 
Gynecology; James Balducci, MD, Chief, Division of 
Obstetrics; James F. Reed Ill, PhD, Director of Health 
Studies; Stephen K. Klasko, MD, Chairperson, 
Department of Obstetrics and Gynecology; and Orion A. 
Rust, MD, Chief, Section of Clinical Obstetrics. 
The second article - "Preeclampsia: Immunologic 
Alteration of Nitabuch's Membrane? Clinical Sequelae" -
was authored by James Balducci, MD, Patrice M. 
Weiss, MD, Robert 0. Atlas, MD, Section of Maternal-
Fetal Medicine; Marc F. Pajarillo, Work Study student; 
( 
William B. Dupree, MD, Chief, Division of Gynecologic 
. Pathology; and Stephen K. Klasko, MD. 
lndru T. Khubchandani, MD, Division of Colon and 
Rectal Surgery, was on the guest faculty of the Annual 
Meeting of the Association of Colon and Rectal Surgeons 
of India in Bangalore from December 29 to January 4. 
He gave a lecture on "Hemorrhoidectomy Under Special 
Circumstances- Dialysis, Positive HIV, Hematologic 
Disorders, and Pregnancy." He also moderated a 
symposium on the "Special Use of Staplers in Colorectal 
Surgery." 
The Association of Surgeons of India presented Dr. 
Khubchandani with a "Distinguished Services Award for 
Outstanding and Dedicated Contribution." A plaque, 
along with a silver plate, was presented. 
Upcoming Seminars, Conferences 
and Meetings 
Medical Grand Rounds 
Medical Grand Rounds are held every Tuesday from 
Noon to 1 p.m., in the hospital's Auditorium at Cedar 
Crest & 1-78. 
Topics to be discussed in February include: 
... 
+ February 3 - Hyperparathyroidism 
+ February 10 - Fever of Unknown Origin in the 
Critically Ill 
+ February 17 - Update in Physical Diagnosis • Part 2 
+ February 24- To be announced 
For more information, please contact Evalene Patten in 
the Department of Medicine at 402-1649. 
Department of Pediatrics Conferences 
Pediatric conferences are held on Fridays beginning at 
Noon, in the hospital's Auditorium at 17th & Chew. 
Topics to be discussed in February include: 
• February 13 - Approach to Office Clinical Research 
+ February 27- HIV Update 
For more information, please contact Kelli Ripperger in 
the Department of Pediatrics at 402-2540. 
Psychiatric Grand Rounds 
The Department of Psychiatry will hold its monthly Grand 
Rounds presentation on Thursday, February 19, from 
Noon to 1 p.m., in the Auditorium at 17th & Chew. 
"Alcohol and the Axis I Patient" will be presented by 
Laurence P. Karper, MD, Medical Director of Behavioral 
Health, Crisis Emergency. 
For more information, contact Bruce Curry in the 
Department of Psychiatry at 402-2705. 
(Continued on Page 12) 
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(Continued from Page 11) 
"The Gender Gap" 
"The Gender Gap" Women & Cardiovascular Disease, a 
conference for physicians, nurses, cardiac rehabilitation 
specialists, and other health care professionals, will be 
held on Saturday, March 7, from 7:30 a.r:n. to 1:15 p.m., 
at the Gateway Conference Center (Holiday Inn), Routes 
22 & 512, Bethlehem. 
Conference objectives include: 
• Describe cardiovascular risk factors and future 
strategies in prevention of cardiovascular disease in 
women 
• Identify myths related to cardiovascular disease in 
women 
• Discuss healing in relationship to mind, body and 
spirit 
• Identify dietary issues specific to women in 
prevention of cardiovascular disease 
• Describe the benefits of cardiac rehabilitation and 
identify the uses of clinical practice guidelines for 
cardiac rehabilitation programs. 
The conference is sponsored by the American Heart 
Association. For more information, call867-0583. 
Legal Update for Physicians 
"How Physicians Survive in a Litigious World" will b{ 
presented on Saturd~y, February 21, from 7:30 a.m. to 
Noon, in the hospital's Auditorium at Cedar Crest & 1-78. 
Speakers will include Janina Fiesta, BSN, JD, Vice 
President, Legal Affairs, who will present "Decreasing the 
Stress of Litigation: Information is Power," and Joseph 
Romano, Esq., who will discuss "Managed Care: Ethical 
Dilemmas for Physicians." 
For more information or to register for the program, 
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Who's New 
The Who's New section of Medical Staff Progress Notes contains an 
update of new appointments, address changes, status changes, etc. 




Michele A. Bemardich, DMD 
(solo) 
1050 S. Cedar Crest Blvd. 
Suite 104 
Allentown, PA 18103-5454 
(610) 437-7993 
Department of Dentistry 
Division of Orthodontics 
Provisional Active 
Ellen B. Bishop, MD 
L VPG-Pediatrics 
Lehigh Valley Hospital 
17th & Chew 
PO Box7017 
Allentown, PA 18105-7017 
(610) 402-2540 
Fax: (610) 402-9674 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
John M. Brown, MD 
Health Network Laboratories 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-4260 
Department of Pathology 
Division of Clinical & Anatomic Pathology 
Provisional Active 
Anthony L. Dimick, MD 
ABC Family Pediatricians 
Bath Community Medical Center 
6649 Chrisphalt Drive 
Bath, PA 18014-8501 
(610) 837-8188 
Fax: (610) 837-7344 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
William J. Liaw, DO 
Primary Care Associates in the LV, PC 
1028 N. 19th Street 
Allentown, PA 18104-3762 
(610) 437-1288 
Fax: (610) 437-6517 
Department of Family Practice 
Provisional Active 
Clifford H. Lyons, MD 
Hamburg Family Practice Center 
260 State Street · 
Hamburg, PA 19526-1823 
(610) 562-3066 
Fax: (610) 562-3125 
Department of Family Practice 
Provisional Active 
Dion Manhoff, MD 
Health Network Laboratories 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2260 
Department of Pathology 
Division of Clinical & Anatomic Pathology 
Provisional Active 
Mari A. McGoff, MD 
Tilghman Urgent Care 
4825 Tilghman Street 
Allentown, PA 18104-9374 
(610) 366-9242 
Fax: (610) 366-9229 
Department of Medicine 
Division of General Internal Medicine 
Provisional Associate 
Sethuraman Muthiah, MD 
Lehigh Valley Medical Associates 
1255 S. Cedar Crest Blvd. 
Suite 2200 
Allentown, PA 18103-6256 · 
(610) 437-9006 
Fax: (610) 437-1942 
Department of Medicine 
Division of General Internal Medicine 
Provisional Active 
Susan K. Pedott, DMD 
Mark R. Eisner, DMD 
Atrium Building 
2895 Hamilton Blvd. 
Suite 205 
Allentown, PA 18104-6172 
(610) 435-2303 
Department of Dentistry 
Division of Endodontics 
Provisional Active 
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Change of Status 
Joseph W. Gastinger, MD 
Department of Medicine 
Division of General Internal Medicine/Geriatrics 
From Active/LOA to Active 
Henry E. Lehrich, MD 
Department of Family Practice 
From Active to Honorary 
Paul J. Lynott, MD 
Department of Family Practice 
From Affiliate to Provisional Active 
Robert D. Strauss, MD 
Department of Surgery 
Division of Otolaryngology 
From Active to Affiliate 
Thomas A. Ward, MD 
Department of Surgery 
Division of Orthopedic Surgery 
From Active to Affiliate 
Change of Practice 
Kenneth A. Bernhard, MD 
Department of Medicine 
Division of Cardiology 
From InterValley Cardiology 
to Lehigh Valley Cardiology Associates 
2597 Schoenersville Road 
Suite 202 
Bethlehem, PA 18017-7396 
(610) 866-2233 
Fax: (610) 866-7738 
M. Carol Greenlee, MD 
Department of Medicine 
Division of Endocrinology/Metabolism 
No longer with Merkle, Barilla & Doll 
New Practice: Endocrinology, Diabetes & Metabolism 
17th & Chew, PO Box 7017 
First Floor, Suite 1 S01 
Allentown, PA 18105-7017 
(610) 402-9566 
Fax: (610) 402-9688 
(Effective 2/2/98) 
Paul J. Lynott, MD 
Department of Family Practice 
From Northampton Medical Associates, Inc. 
to Emmaus Medical Associates, Inc. (LVPG) 
111 E. Harrison Street 
Emmaus, PA 18049-2997 
(610) 967-4147 
Fax: (610) 965-3837 
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William M. Markson, MD 
Department of Medicine 
Division of Cardiology 
From InterValley Cardiology 
to The Heart Care Group, PC 
451 Chew Street 
Suite 302 
Allentown, PA 18102-3423 
(610) 821-2810 
Fax: (610) 821-6952 
Eugene E. Ordway, MD 
Department of Medicine 
Division of Cardiology 
From InterValley Cardiology 
,to John J. Cassel, MD, PC 
1255 S. Cedar Crest Blvd. 
SUite 1200 
Allentown, PA 18103-6256 
(610) 437-6222 
Fax: (610) 437-5910 
Ronald A. Stein, MD 
Department of Medicine 
Division of Cardiology 
From InterValley Cardiology 
to The Heart Care Group, PC 
451 Chew Street 
Suite 302 
Allentown, PA 18102-3423 
(610) 821-2810 
Fax: (610) 821-6952 
Syed A. Subzposh, MD 
Department of Medicine 
Division of Cardiology 
From InterValley Cardiology 
to The Heart Care Group, PC 
451 Chew Street 
Suite 302 
Allentown, PA 18102-3423 
(610) 821-2810 




Address and/or Telephone Number Changes 
Weldon E. Chafe, MD 
1240 S. Cedar Crest Blvd. 
Suite 114 
Allentown, PA 18103-6218 
(610) 402-0630 
Fax: (610) 402-0644 
Peter H. Goldman, MD 
1251 S. Cedar Crest Blvd. 
Suite 102C 
Allentown, PA 18103-6294 
( 
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Gregory R. Harper, MD 
1240 S. Cedar Crest Blvd. 
( )uite 114 
· Allentown, PA 18103-6218 
(61 0) 402-0630 
( 
Fax: (610) 402-0644 
Charles R. Levine, MD 
421 Chew Street 
Allentown, PA 18102 
(610) 776-5477 
Fax: (610) 776-5479 
Practice Name Change 
ABC Family Pediatricians 
Sangeeta Agrawala, MD 
Scott M. Brenner, MD 
Anthony L. Dimick, MD 
Thomas J. Durkin, MD 
Pasquale J. Fugazzotto, MD 
Elizabeth Goff, MD 
Dennis W. Kean, MD 
Debra L. Kruse, MD 
Donald L. Levick, MD 
Elmer C. Long, MD 
David J. Meehan, MD 
Renee D. Morrow-Connelly, DO 
Amil M. Qureshi, DO 
Michael D. Schwartz, MD 
Patricia L. Shoemaker, MD 
Mary B. Stahl Levick, MD 
Allentown Family Health Specialists 
Anthony P. Buonanno, MD 
Bruce A. Ellsweig, MD 
Linda S. Loffredo, MD 
Rush-Spinosa Family Practice 
Wendy J. Rush-Spinosa, MD 
Assignments to New Division of Hand 
Surgery 
Michael A. Chemofsky, MD 
Raj P. Chowdary, MD 
Geoffrey G. Hallock, MD 
Robert B. Kevitch, MD 
Robert X. Murphy, Jr., MD 
Walter J. Okunski, MD 
JayS. Talsania, MD 
Appointment to Medical Staff Leadership 
Position 
Michael A. Chemofsky, MD 
Department of Surgery 
Division of Plastic & Reconstructive Surgery/Hand Surgery 
Chief, Division of Hand Surgery 
Resignations 
Mary W. Clark, MD 
(Milton S. Hershey Medical Center) 
Department of Surgery 
Division of Orthopedic Surgery 
Provisional Associate 
Theodore J. Matulewicz, MD 
(Lehigh Valley Pathology Associates) 
Department of Pathology 
Division of Clinical & Anatomic Pathology 
Active 
Leonard A. Merlo, DMD 
(Allen Oral Surgery Associates) 
Department of Surgery 
Division of Oral and Maxillofacial Surgery 
Active 
Roy E. Monsour, MD 
(L VPG-Emergency Medicine) 
Department of Emergency Medicine 
Division of Emergency Medicine 
Active 
Deaths 
Peter M. Anson, MD 
(Lehigh Valley Orthopedics) 
Department of Surgery 
Division of Orthopedic Surgery 
Active 
11/21/97 
Robert J. Beitel, Jr., MD 
Department of Surgery 
Division of Ophthalmology 
Honorary 
11/5197 
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Anesthesia Tech Assistant 
(Allentown Anesthesia Associates Inc- Alphonse Maffeo, MD) 
Christopher J. Bury 
Physician Extender 
Technical 
Anesthesia Tech Assistant 
(Allentown Anesthesia Associates Inc- Alphonse Maffeo, MD) 




(Pulmonary Associates - Jonathan Hertz, MD) 




(Orthopaedic Associates of Allentown -Thomas Meade, MD) 




(John J. Cassel, MD, PC- John Cassel, MD) 




(The Heart Care Group, PC - Michael Rossi, MD) 




(Allentown Anesthesia Associates Inc - Alphonse Maffeo, MD) 




(Allentown Anesthesia Associates Inc - Alphonse Maffeo, MD) 








Anesthesia Tech Assistant 
(Allentown Anesthesia Associates Inc - Alphonse Maffeo, MD) 




(Orthopaedic Associates of Allentown - Patrick Respet, MD) 




(OBGYN Associates of the Lehigh Valley - Ernest Normington, MD) 




(Allentown Anesthesia Associates Inc -Alphonse Maffeo, MD) 
Change of Supervising Physician 
( 
Christopher A. Fry, PA·C 
Physician Extender 
Physician Assistant ( 
PA-C 
From Lehigh Valley Orthopedics - Charles Levine, MD 
to Coordinated Health Systems- Carl Weiss, Jr., MD 




From Ear, Nose & Throat Assoc of LV, Inc.- Robert Strauss, MD 
to Allen Ear, Nose & Throat Associates - Thomas Koch, MD 
Resignations 




(Allentown Anesthesia Associates Inc) 
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TESTING UPDATE: FOCUS ON SPECIAL COAGULATION TESTING 
Thrombotic disease accounts for 300,000- 600,000 hospitalizations and approximately 100,000 
deaths annually in the United States. Each year approximately 1 out ofevery 10,000 individuals in 
the United States will have a venous or arterial thrombotic event; greater than 250,000 persons in the 
United States are diagnosed annually with venous thromboembolism. The causes of 
thromboembolism can be divided into primary, those being found in patients with deficiencies of 
specific coagulation proteins, and secondary, those being associated with other clinical conditions 
such as malignancy, myeloproliferative disease, hyperlipidemia, and nephrotic syndrome. Because 
the hereditary or acquired disorders of thrombosis sometimes may not be distinguished from one 
another by clinical presentation, the evaluation of these disorders should be performed initially with 
functional coagulation assays when the patient is not anticoagulated. Anticoagulant therapy can 
interfere with assay validity. Many patients experience thrombosis or thromboembolic events only 
when a combination of factors increases the risk of thrombosis--the so-called "multiple hit" or 
cumulative effect. It is essential that a detailed history and physical examination be performed in 
order to disclose any conditions that may contribute to thrombosis formation. Lastly, accurate 
selection of hemostasis assays to support, confirm or rule out a diagnosis is crucial. The decision to 
investigate thrombophilia should be made on an individual basis, but patients with any of the 
following may require special consideration: 
+ DeNovo venous thrombosis under the age of 45 years 
+ Recurrent venous thrombosis 
+ Family history of venous thrombosis 
+ Family history of thrombophilic abnormality 
+ Venous thrombosis in an unusual site 
+ Spontaneous neonatal thrombosis 
· + Arterial thrombosis under the age of 30 years 
+ Thrombosis during pregnancy 
As an aid in the diagnosis and management of these diseases, Health Network Laboratories will be 
expanding its special coagulation test capabilities over the next few months. The following 'is a list of 
the new tests available on a single order basis. Also included is a description of updates that will be 
made to existing profiles. 
Questions or concerns should be directed to Dr. David Prager, Medical Director Hematology and 
Coagulation. Reference lists available by request through Health Network Laboratories, Gale Fritch 
MT, (ASCP), SC, Slat 402-8170, 
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Dilute Russell viper venom time (dRVTT) with reflex confirmation 
This test is primarily used as a lupus anticoagulant screen in conjunction with the PTI. Medical literature ( 
guidelines suggest using at least two screening tests to significantly enhance the detection of lupus 
anticoagulants. 
Anti-Beta-2-Giycoprotein-1 antibodies 
This assay measures "total" antibodies to beta-2-glycoprotein-1, the major protein now considered the target 
antigen for anti-Cardiolipin antibodies. Current studies suggest that positivity may be more closely associated with 
clinical manifestations than that seen with conventional Cardiolipin assays. 
APC Resistance 
This PTI-based assay is reported as a ratio and reflects anticoagulant response to activated protein C (APC). 
APC resistance is currently the most common inherited risk factor for clinically significant venous thrombosis. It is 
present in 3-5% of the Caucasian population, and may be found in approximately 40% of patients with recurrent 
thrombosis. The majority of patients found to be APC resistant have a single nucleotide mutation in the Factor V 
gene. 
Factor V Leiden Mutation 
This PCR assay is best utilized as a follow-up in patients with previously abnormal test results for the APC 
resistance assay. Testing evaluates the sequence coding for the arginine to glutamine substitution at position 506 
of the factor V protein. 
Homocysteine 
MTHFR 
This quantitative assay measures "total" homocysteine in the fi§1ing patient. Hyperhomocysteinemia has been 
implicated as an independent risk factor for coronary artery disease, acute Ml, stroke, and venous 
thromboembolism. Elevations may occur in patients with cobalamin and/or folate deficiency and in genetic 
mutations in one of the enzymes that regulate homocysteine metabolism 5,1 a-methylene tetrahydrofolate 
reductase (also known as MTHFR). ( 
This PCR assay is best utilized as a follow-up in symptomatic individuals with increased basal homocysteine 
levels or abnormal methionine-load tests. Testing evaluates the sequence coding for the alanine to valine 
substitution in position 223 of the enzyme methylene tetrahydrofolate reductase. 
PROFILE UPDATES 
These "profiles" represent clinically useful groupings of tests. Each test is billed separately. Each test is available 
separately as a single test order. Please assure your order represents only those tests medically necessary for 
the diagnosis of each patient's disease. 
Lupus anticoagulant profile 
To include: Thrombin time, PTI (lupus sensitive), dRVTT/screen. 
Confirmatory tests: PTI mix, Platelet neutralization, and dRVTT/confirmation performed as 
required. 
Antiphospholipid antibody profile (formerly LUA Profile) 
To include: Thrombin time, PTI (lupus sensitive), dRVTT screen, Anti-cardiolipin lgG and lgM, and Anti-beta-
2-glycoprotein-1 antibodies. 
Confirmatory tests performed as required. 
Thrombotic risk profile (formerly Hypercoagulability profile) 
To include: Thrombin time, PTI (lupus sensitive), dRVTT screen, Anti-cardiolipin lgG and lgM, 
Anti-beta-2-glycoprotein-1 antibodies, Fibrinogen, Plasminogen activity, Antithrombin Ill activity, ( 
APC resistance, functional Protein C and Protein S. 
Confirmatory tests performed as required. 
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(THERAPEUTICS AT A GLANCE 
fhe following actions were taken at the September-December 1997 Therapeutics Committee Meeting- Maria Barr, Pharm.D.,BCPS, 





The Therapeutics Committee recently approved 
subcommittee recommendations on the use of 
transmucosal fentanyl citrate (Fentanyl Oralet®) 
at L VH. This agent is indicated for use In. a 
hospital setting as an anesthetic pre-medication in 
the operating room or to induce conscious 
sedation prior to a diagnostic or therapeutic 
procedure in anesthesia care settings. 
Representatives from Pharmacy, Emergency 
Medicine, Pediatrics, Anesthesia, and Pain 
Management met to discuss the potential role of 
( )ral transmucosal fentanyl in the institution. 
Based on all data presented, the following 
recommendations were made: 
1) Hold the us~ of oral transmucosal fentanyl in the 
Emergency Department for now, pending the 
completion of current ongoing studies, with the 
possibility of an in-house study in the future. 
2) Utilize oral transmucosal fentanyl in those situations 
where intravenous access is not established or 
adequate and sedation is required, as in the bum 
patient. 
3) Utilization of oral transmucosal fentanyl is restricted 
to those physicians authorized to participate in the 
conscious sedation protocol of L VH. A "QA 
• • • I Cntena Sheet" w11I be developed and attached to 
each oral transmucosal fentanyl dose. This would 
assure that the conscious sedation protocol is 
observed. 
The recommendations were approved by the 
Therapeutics Committee at the meeting on 




The L VH formulary has expanded it's spectrum 
of antibiotics to include azithromycin IV 
(Zithromax®), cefepime (Maxipime®), and 
levofloxacin PO and IV (Levaquin®). The 
addition of the agents and the criteria specified 
for each drug were developed in co~unction with 
the L VH Department of Infectious Disease. 
In addition to PO/IV erythromycin and 
clarithromycin (Biaxin®), azithromycin 
(Zithromax®, Pfizer), will be available in both 
PO/IV formulations as an alternative to other 
macrolides or doxycycline for suspected atypical 
organisms causing pneumonia. Azithromycin is 
FDA approved for the treatment of community-
acquired pneumonia and pelvic inflammatory 
disease. 
Azithromycin is administered once daily. 
Another important difference among the 
macrolides is their potential to cause drug-drug 
interactions (See table). Azithromycin may be 
chosen as an alternative to avoid significant drug-
drug interactions. Careful monitoring should be 
considered in patients receiving theophylline, 
warfarin, ergotamine, and other drugs . 
metabolized by the cytochrome P450 system. 
The most common adverse reactions with 
azithromycin include gastrointestinal (diarrhea, 
nausea, abdominal pain, and vomiting), infusion 
related reactions (pain, inflammation), rash and 
pruritus. With the availability of a tablet 
formulation, azithromycin can be administered 
without regard to meals, to help reduce GI side 
effects. The most frequent laboratory 
abnormalities consist of elevated 
aminotransferases, LDH, and bilirubin. The 
table below summarizes dosing and cost 
comparison between similar agents. 
* Azithromycin 500mgxl fib 
* Azithromycin 500mg IV QD 
*Erythromcyin lgm IV Q6H 
*Doxycycline lOOmg IV Q12H 
$9.90 day 11 





Guidelines established per the Therapeutics 
Committee restricts the use of intravenous 
azithromycin to .1.) patients who are NPO 
including medications,· 2.) patients requiring 
fluid restriction; and 3.) patients with peripheral 
access. In patients who fail to meet the above 
criteria and who require parental atypical 
pneumonia therapy, doxycycline or erythromcyin 
remain the L VH treatment of choice. 
MACROLIDEIAZOLIDE DRUG INTERACTIONS 
Azlthro Tab Clarlthro Erythro (Base) 
Food/enteral 
AnlaCids Avoid Avoid 
Antihistamines 
astemizole Avoid Avoid 
(Hismanal") 
loratadine A'l'oid A'l'oid 
terfenadlne A '!'Old A '!'Old 
(Seldane ~ 
cetrlzine Safe Safe Safe 
(Zyrtec:R} 
cllapride Safe Avoid A'l'oid 
(PropuJddR) 
cyclosporlne Safe •• •• 
carbamazepine Safe •• •• 
(TegretoJR) 
tac:rolbnus Safe •• •• 
(Prograt") 
theophyDine Safe .... •• 
warfarin Safe •• •• 
(CoumadiJIR) 
'"old · mtcniCtlon note( avoid concomuant lll1lllllllStrallon 
Safe - no drug imeraction 
** Drug-Drug interactions requiring monitoring and possible dose changes 
CEFEPIME - FOUR 
GENERATIONS AT L VH 
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The L VH Therapeutics Committee approved for 
formulary addition cefepime (Maxipime~, 
Bristol-Myers Squibb Company), the parenteral 
fourth generation cephalosporin. The ftrst of the 
fourth generation cephalosporins, cefepime may 
be described as an enhanced ceftazidime 
(Fortaz~. Relative to ceftazidime, cefepime 
possesses a similar spectrum of activity against 
gram negative organisms, possibly improved 
activity against Enterobacter sp., and activity 
against some gram positive organisms. In 
addition to the FDA indications below, cefepime 
possesses in vitro activity against a number of 
aerobic gram positive and gram negative 
organisms, but well controlled clinical studies 
have not been performed for all organisms. The 
FDA approved indications for cefepime are as 
follows: 
1. uncomplicated and complicated urinary tract 
infections, including pyelonephritis, with specific 
in vitro data for Escherichia coli, Klebsiella 
( 
pneumoniae, Proteus mirabilis 
uncomplicated skin and skin structure infections, ( 2. 
3. 
4. 
specific in vitro data for Staphylococcus aureus and 
Streptococcus pyogenes 
moderate to severe pneumonia with specific in vitro 
data for Streptococcus pneumoniae, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, and 
Enterobacter species . 
empiric therapy for febrile neutropenic patients. 
Like all cephalosporins, cefepime acts via 
inhibition of cell wall synthesis, attaching to 
penicillin binding proteins to promote cell lysis. 
Unique to the cephalosporins, cefepime's 
chemical structure includes a zwitterion . 
which produces a net neutral charge that 
improves entrance through the bacterial outer 
membrane. The inclusion of a side chain 
substitution promotes increased stability to beta-
lactamases. 
Pharmacokinetically, cefepime is similar to other 
cephalosporins. Pharmacokinetic highlights 
include bioavailability of 100% when 
administered via 1M injection, but peak plasma ( 
concentration two to three time lower than when · 
administered via theN route. Cefepime 
distributes to many tissues and fluids ie. 
bronchial mucosa, the appendix, peritoneal fluid, 
( Jile fluid, gallbladder tissue, and may also cross 
the inflamed blood brain barrier. Also, cefepime 
is excreted 85% unchanged in the urine, with 
clearance closely approximating glomerular 
filtration rate. 
( 
In general, the most common adverse drug 
reactions with cefepim.e include local reactions 
(phlebitis, pain +/- inflammation), headache, 
nausea. rash. and diarrhea. The most common 
laboratory abnormalities include positive 
Coomb's test (w/o hemolysis), hypo-
phosphatemia, increased transaminases, 
eosinophilia, and slightly abnormal increases in 
prothrombin time and activated partial 
thromboplastin time. Precautions/ 
contraindications apply for those with 
hypersensitivity to penicillins, cephalosporins, or 
other beta-lactams, ·depending on the severity of 
the patients allergy. 
Cefepime may be administered via direct IV 
.mtravenous injection (over 3 to 5 minutes), via 
infusion (over 20-30 minutes), or via deep IM 
injection. For the majority of infections, 
cefepime may be dosed at 0.5 to 2 grams Q12H. 
An exception to this is the FDA approved 
indication for monotherapy in febrile 
neutropenia, where dosing is 2 gram IV Q8H. 
(Please see below for Therapeutics Committee 
Recommendations). The manufacturers dosing 
guidelines for renal dysfunction (excluding 
neutropenic fever regimens) are as follows: for 
creatinine clearance (CrCl) based on Cockroft 
and Gault. 
CrCl 
> 60 mllmin 
30-60 ml/min 
11-29 mllmin 
< 11 mllmin 
Dose 
as above 
0.5 to 2 gram Q24H 
0.5 to 1 gram Q24H 
0.25 to 0.5 grams Q24H 
The addition of cefepime to the L VH formulary 
offers several advantages, including the potential 
to serve as an alternative to ceftazidime. Relative 
to ceftazidime, cefepime offers: 1) broader 
aerobic gram positive coverage, 2) the potential 
for improved Enterobacter sp coverage, 3) less 
frequent administration and 4) cost savings 
potential (See table below). The therapeutic 
disadvantages include the 1) limited/lacking 
clinical data in the pediatric population and 
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2) treatment for febrile neutropenia requires 
monotherapy of 2 gram IV Q8 hours as does 
ceftazidime, which offers no additional efficacy 
for an increase in cost. Given the above 
considerations, the L VH Therapeutics Committee 
voted to add cefepime to formulary with the 
following criteria: 
1) Cefepime will eventually replace ceftazidime on the 
L VH formulary when laboratory susceptibility testing 
becomes more readily available. The FDA is due to 
release new testing cards this month. The House 
Staff will be notified when the replacement occurs. 
2) Once the above occurs, ceftazidime will remain on 
formulary, restricted to use only for the treatment of 
neutropenic fever and for use in the pediatric 
population. 
3) Cefepime 1 gram IV Q12 hours is recommended for 
all infections (in normal renal function) except for 
infection with pseudomonas, where 2 grams IV Q12 
hours should be used. 
Cost Comparison Drug Regimen 
cefepime lgm Q12H 
cefepime 2gm Q12H 
cefepime 2gm Q8H 
ceftazidime lgm Q8H 









Levofloxacin (Levaquin~~D, Ortho McNeil 
Pharmaceuticals), the /-isomer of ofloxacin, is 
now introduced to the L VH formulary. ·Current 
fluroquinolones on formulary include norfloxacin 
(urinary tract infections only) and ciprofloxacin 
(systemic and urinary tract infections). Like 
ciprofloxacin, levofloxacin possesses 
bacteriocidal activity against many aerobic gram 
negative and atypical organisms, but the inclusion 
of a methyl group at the 7-position of the 
quinolone nucleus broadens the spectrum to 
include activity against streptococci. 
Like other fluroquinolones, levofloxacin's 
bacteriocicJal activity occurs secondary to the 
inhibition of DNA gyrase, which alters the 
bacterial DNA synthesis. Levofloxacin possesses 
in vitro activity against a number of aerobic gram 
positive and gram negative organisms, but well 
controlled clinical studies have not been 
performed for all organisms. The minimal 
inhibitory concentration (MIC) for Pseudomonas 
aeruginosa for levofloxacin and cipt::ofloxacin are 
4ug/ml and 0.5ug/ml, respectively. The clinical 
significance of this difference is unknown. The "' 
following are the FDA indications which include 
the microorganisms for which in vitro testing and 
clinical studies have been established: 
1. Acute maxillary sinusitis (due to Streptococcus 
pneumoniae, Haemophilus injluenzae or Moroxella 
catarrhalis) 
2. Acute bacterial exacerbation of chronic bronchitis (as 
with sinusitis above plus Staphylococcus aureus, and 
Haemophilus parainjluenzae) 
3. Community acquired pneumonia (as with bronchitis 
above and Klebsiella pneumoniae, chlamydia 
pneumoniae, Legionella pneumophila, or 
Mycoplasma pneumoniae) 
4. Uncomplicated skin and skin structure infections 
(due to Staphylococcus aureus or Streptococcus 
pyogenes) 
5. Complicated urinary tract infections (due to 
Enterococcus faecalis, Enterobacter cloacae, 
Escherichia coli, Klebsiella pneumoniae, Proteus 
mirabilis, or Pseudomonas aeruginosa) 
6. Acute pyelonephritis (due to Escherichia coli). 
Levofloxacin is available in both oral and IV 
formulations. With respect to pharmacokinetics, 
levofloxacin is approximately 100% bioavailable; 
therefore, the formulations, are interchangeable. 
Levofloxacin distributes widely into body tissues. 
Renal excretion is the principle mode of 
elimination, with tubular secretion and 
glomerular filtration occurring. The plasma 
elimination half-life is between 6 to 8 hours. 
Dosing adjustments are necessary in the renally 
impaired. (See dosing information below). 
Awareness of several pertinent drug-drug 
interaction is necessary with levofloxacin 
therapy. As with other quinolones, antacids, 
sucralfate, metal cations and multi-vitamins may 
chelate levofloxacin and decrease systemic 
concentrations of the quinolone. Separation of a 
minimum of two hours before or after 
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levofloxacin administration is required. Also, 
the coadministration of quinolones with NSAIDS 
may enhance the potential for CNS stimulation ( 
and convulsive seizures. Lastly, the following 
agents have demonstrated no significant drug-
drug interaction with levofloxacin, but require 
cautious use· and monitoring as other 
fluoroquinolones have been associated with drug-
drug interactions - theophylline, warfarin, 
cyclosporine, and digoxin. · 
Cautions, Contraindications, Warnings and 
Precautions with levofloxacin use are as with 
other fluroquinolones. The most common 
adverse drug interactions include gastrointestinal 
disturbances (nausea, diarrhea, abdominal pain, 
dyspepsia, constipation, vomiting), headache, 
insomnia, dizziness, rash and vaginitis. Potential 
laboratory abnormalities may include alterations 
in a blood glucose, and decreases in 
lymphocytes. 
As noted above, levofloxacin may be 
administered orally, and by IV infusion (over a 
minimum of 60 minutes). Dosing for both the ( 
oral and IV formulations are the same, as the 
bioavailability is 100%. This creates an economic 
advantage, making early oral therapy a rational 
option. Find below tables adapted from th~ 
manufacturers product monograph for dosing in 
normal and in impaired renal function. Please 
note that the creatinine clearance (CrCl) values 
are based on Crockroft Gault calculations. The 
cost data is summarized at the end of this 
section. 
PATIENTS WITH NORMAL RENAL FUNcTION: 
Infection Dose Freg Duration Daily Dose 
Acute Bacterial 500mg Q24H 7 days 500mg 
Exacerbation of 
Chronic Bronchitis 
Comm, Acquired 500mg Q24H 7-14 days 500mg 
Pneumonia 
Acute Maxillary 500mg Q24H 10-14 days 500mg 
Sinusitis 
Uncomplicated 500mg Q24H 7-10 days 500mg 
SSSI 
Complicated UTI 250mg Q24H 10 days 250mg 
Acute 
pyelonephritis 250mg Q24H 10 days 250mg ( 
... 
PATIENTS WITH IMPAIRED RENAL FUNCfiON: 
( 1enal Status Initial Dose Subsequent Dose 
Acute Bacterial Exacerbation of Chronic Bronchitis/ 




CrCl from 50 to 80 mL/min No dosage adjustment required 
CrCI from 20 to 49 mL/min 500mg 250mg Q24H 
CrCl from 10 to 19 mL/min 500mg 250mg Q48H · 
Hemodialysis 500mg 250mg Q48H _. 
CAPO 500mg 250mg Q48H 
Complicated U11/ Acute Pyelonephritis 
CrCl ~ 20mL/min No dosage adjustment required 
CrCl from 10 to 19 mL/min 250mg · 250mg Q48H 
CrCl = creatinine clearances 
CAPO = chronic ambulatory peritoneal dialysis 
The therapeutic and formulary benefits for 
levofloxacin include the following: 
1. provision of a therapeutic alternative to current 
standard therapies for the above FDA indications, 
especially when patients may have allergies. 
2. extension of the spectrum to include Streptococcus 
pneumoniae compared to that of ciprofloxacin 
3. QD administration vs. Q12H with ciprofloxacin 
4. equal bioavailability for the IV and oral 
formulations, promoting the early use of oral therapy 
and resultant cost benefit. 
Conversely, the therapeutic disadvantages 
include: 
1. the potential for overuse/misuse of this broad 
spectrum agent which may promote the development 
of resistant organisms. 
2. if increased resistance occurs, the potential adverse 
patient outcomes and cost to die institution are very 
concerning. 
3. lack of data for levofloxacin use in the HIV 
population prohibits the deletion of ciprotloxacin 
from formulary, i.e. multiple formulary options are 
needed. 
4. current laboratory susceptibility testing is of limited 
availability. (As with cefepime, the FDA gram 
negative testing card revisions will hopefully solve 
this problem). 
Given these considerations the L VH Therapeutics 
Committee voted to add levofloxacin IV and oral 
formulations to the formulary, with the 
understanding that routine susceptibility testing 
is unavailable. Susceptibility testing may be 
ione only by specific request, until the routine 
testing options are available. 
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When prescribing levofloxacin at L VB please 
remember to completely write out the word 
"levofloxacin." Concern has been expressed 
over the potential for miscommunication when 
the term "levo" is used (ie. confusion with 
"LevophedaD" or levothyroxine). 
Cost Comparison Data 
Agent 
levotloxacin 500mg IV QD 
levofloxacin 250mg PO QD 
levofloxacin 500mg PO QD 
ciprofloxacin 400mg IV Q12H 
ciprofloxacin 200mg IV Q12H 
ciprofloxacin 250mg PO Q12H 
ciprofloxacin 500mg or 









A REMINDER ... Flumazenil 
(Romazicon®) Use for Reversal 
of Benzodiazepines 
Due to hospital-wide use of the conscious 
sedation guidelines, please be aware of 
appropriate use of flum.azenil to reverse 
benzodiazepines. Fll:unazenil (RomaziconaD) 
works to reverse benzodiazepines (ie. 
midazolam, lorazepam) by displacing the 
benzodiazepine from the GABA receptor. Please 
note flum.azenil has a shorter half-life than the 
shortest acting benzodiazepines (midazolam). As 
a result, patients may have a reversal of sedation 
with flumazenil but may become resedated once 
flumazenil is metabolized. . Please monitor all 
patients for at least 2 hours after flumazenil is 
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